Australian listed drug development company, Nyrada Inc. (ASX: NYR) reported that both the potent drug candidates-NYX-242 and NYX-1010 can be given via preferred route of administration for moderate-severe TBI and stroke patients, with desired pharmacokinetic profiles for clinical studies.
In the preclinical pharmacokinetic study, both the lead preclinical drug candidates achieved durable therapeutic levels when continuous intravenous administration of the drug candidates was maintained.
Both compounds, in the uninjured brain of a second animal species, were seen to readily cross the blood-brain-barrier, with no observed adverse effects after continuous dosing for 6 hours.
Nyrada is currently carrying out the study for testing intranasal drug delivery, which is the preferred route for treatment of mild traumatic brain injury and concussion injury, common in sports.
NYR traded at $0.215, up 2.4% on 15 July 2020 (12:33 PM AEST).
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.